EAM
CCCC icon

Erste Asset Management’s C4 Therapeutics CCCC Stock Holding History

Erste Asset Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,700
Closed -$29.4K – 551
2023
Q2 		$29.4K Hold
10,700
– – ﹤0.01% 551
2023
Q1 		$33.2K Hold
10,700
– – ﹤0.01% 560
2022
Q4 		$61.6K Hold
10,700
– – ﹤0.01% 542
2022
Q3 		$91.4K Hold
10,700
– – ﹤0.01% 524
2022
Q2 		$78.5K Hold
10,700
– – ﹤0.01% 540
2022
Q1 		$258K Buy
+10,700
New +$260K ﹤0.01% 494

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Erste Asset Management's CCCC Position: Q3 2023 in Review

Erste Asset Management sold out of C4 Therapeutics (CCCC) in Q3 2023, closing a stake of 10,700 shares — an estimated $29.4K sold.

Erste Asset Management first reported a position in CCCC in Q1 2022 and held it in 6 quarters. The position peaked at $258K in Q1 2022. 83 funds tracked by Wall St. Rank hold CCCC as of Q3 2023.

  • Erste Asset Management reported no remaining C4 Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Erste Asset Management sold 10,700 C4 Therapeutics shares in Q3 2023, an estimated $29.4K.
  • Erste Asset Management first reported a position in C4 Therapeutics in Q1 2022 and held it in 6 quarters.
  • Erste Asset Management's C4 Therapeutics position peaked at $258K in Q1 2022.
  • 83 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2023.

Based on Erste Asset Management's 13F filing for Q3 2023, filed 26 Nov 2024.